Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yannick Marie

Showing results (71-80 of 96) with videos related to

Pageof 10
Sort By:
Clinical Neurology and Neurosurgery|June 20, 2020
Initial surgical resection and long time to occurrence from initial diagnosis are independent prognostic factors in resected recurrent IDH wild-type glioblastomaAntoine Seyve, Fernando Lozano-Sanchez, Alice Thomas, et al.
Neuro-Oncology|December 17, 2013
Clinical value of chromosome arms 19q and 11p losses in low-grade gliomasAgustí Alentorn, Hinke F van Thuijl, Yannick Marie, et al.
Neuropathology and Applied Neurobiology|July 28, 2023
A threshold for mitotic activity and post-surgical residual volume defines distinct prognostic groups for astrocytoma IDH-mutantSuzanne Tran, Alice Thomas, Ilyes Aliouat, et al.
Annals of Neurology|May 1, 2007
Dynamic history of low-grade gliomas before and after temozolomide treatmentDamien Ricard, Gentian Kaloshi, Alexandra Amiel-Benouaich, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 18, 2010
IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor GroupMartin J van den Bent, Hendrikus J Dubbink, Yannick Marie, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 21, 2015
Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2-Amplified and TP53 Wild-type GlioblastomasMaite Verreault, Charlotte Schmitt, Lauriane Goldwirt, et al.
Scientific Reports|December 3, 2015
Quantifying the heritability of glioma using genome-wide complex trait analysisBen Kinnersley, Jonathan S Mitchell, Konstantinos Gousias, et al.
Annals of Neurology|July 29, 2005
Chromosome 1p loss: a favorable prognostic factor in low-grade gliomasMichèle Kujas, Julie Lejeune, Alexandra Benouaich-Amiel, et al.
Tremor and Other Hyperkinetic Movements (New York, N.Y.)|July 17, 2023
Correction: Association of Rare Genetic Variants in Opioid Receptors with Tourette SyndromeChristel Depienne, Sorana Ciura, Oriane Trouillard, et al.
Journal of Neuro-Oncology|December 10, 2014
VEGFA SNP rs2010963 is associated with vascular toxicity in recurrent glioblastomas and longer response to bevacizumabAnna Luisa Di Stefano, Marianne Labussiere, Giuseppe Lombardi, et al.
Pageof 10

Showing results (71-80 of 96) with videos related to

Sort By:
Pageof 10
Clinical Neurology and Neurosurgery|June 20, 2020
Initial surgical resection and long time to occurrence from initial diagnosis are independent prognostic factors in resected recurrent IDH wild-type glioblastomaAntoine Seyve, Fernando Lozano-Sanchez, Alice Thomas, et al.
Neuro-Oncology|December 17, 2013
Clinical value of chromosome arms 19q and 11p losses in low-grade gliomasAgustí Alentorn, Hinke F van Thuijl, Yannick Marie, et al.
Neuropathology and Applied Neurobiology|July 28, 2023
A threshold for mitotic activity and post-surgical residual volume defines distinct prognostic groups for astrocytoma IDH-mutantSuzanne Tran, Alice Thomas, Ilyes Aliouat, et al.
Annals of Neurology|May 1, 2007
Dynamic history of low-grade gliomas before and after temozolomide treatmentDamien Ricard, Gentian Kaloshi, Alexandra Amiel-Benouaich, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 18, 2010
IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor GroupMartin J van den Bent, Hendrikus J Dubbink, Yannick Marie, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 21, 2015
Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2-Amplified and TP53 Wild-type GlioblastomasMaite Verreault, Charlotte Schmitt, Lauriane Goldwirt, et al.
Scientific Reports|December 3, 2015
Quantifying the heritability of glioma using genome-wide complex trait analysisBen Kinnersley, Jonathan S Mitchell, Konstantinos Gousias, et al.
Annals of Neurology|July 29, 2005
Chromosome 1p loss: a favorable prognostic factor in low-grade gliomasMichèle Kujas, Julie Lejeune, Alexandra Benouaich-Amiel, et al.
Tremor and Other Hyperkinetic Movements (New York, N.Y.)|July 17, 2023
Correction: Association of Rare Genetic Variants in Opioid Receptors with Tourette SyndromeChristel Depienne, Sorana Ciura, Oriane Trouillard, et al.
Journal of Neuro-Oncology|December 10, 2014
VEGFA SNP rs2010963 is associated with vascular toxicity in recurrent glioblastomas and longer response to bevacizumabAnna Luisa Di Stefano, Marianne Labussiere, Giuseppe Lombardi, et al.
Pageof 10